FDA Approves Phase 1 Clinical Trial of Rituximab + AB-101 for Lupus Nephritis Treatment
FDA Approves Phase 1 Clinical Trial of Rituximab + AB-101 for Lupus Nephritis Patients GC Cell, a US affiliate of Artiva Biotherapeutics (referred to as Ativa), has received FDA approval for a phase 1 clinical trial of the NK cell therapy AB-101 for lupus nephritis (LN). This marks the first approval for an allogenic NK […]